Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

ERC Advanced Grant for Meinrad Busslinger

04.11.2011
Meinrad Busslinger, Senior Scientist at the Research Institute of Molecular Pathology (IMP) in Vienna, has been selected to receive an Advanced Investigator Grant by the European Research Council ERC. The grant is worth just under 2.5 Million Euro and will be paid out over a period of five years. It will fund the project “LymphoControl” that investigates the development of immune cells.

ERC Advanced Grants allow exceptional established research leaders to pursue ground-breaking, high-risk projects that open new directions in their respective research fields or other domains. They have been awarded for the fourth time this year. 2284 applications were submitted following the last call.

The grant will fund a project entitled "Transcriptional networks controlling lymphocyte development", or “LymphoControl” in short. The aim of the project is to elucidate how transcription factors regulate the development of B- and T-lymphocytes. These white blood cells are the main players in the body’s adaptive immune system.

They are derived from stem cells in the bone marrow and undergo several stages of differentiation before becoming fully functional, mature lymphocytes of the B- or T-cell lineage. Transcription factors are regulatory proteins encoded in the genome that control key stages in this process. Deregulation of the transcriptional control can severely disrupt the programmed cell fate and cause certain types of blood cancer.

Meinrad Busslinger has a long record in immunological research. He was the first to identify a critical factor, named Pax-5, which activates a B cell specific program in the precursor cells and suppresses alternative pathways. Pax-5 is also involved in the development of acute lymphoblastic leukemia in humans.

The project “LymphoControl” will build on previous research efforts, such as the creation of transgenic mice that carry molecular “tags” at the ends of transcription factors.

Busslinger is excited about the European commitment to basic research: “The ERC grant will allow us to carry out a project which requires massive human and technical resources. We have already established the required know-how and infrastructure, owing to the Austrian Science Fund and our sponsor Boehringer Ingelheim. Now we can really take full advantage of the exceptional facilities at the IMP.” The grant will also open career-paths for young researchers. Six additional scientists will be employed under the ERC-funded project.

Meinrad Busslinger was born in Switzerland in 1952. He studied Biochemistry at the ETH Zurich and obtained a doctorate in molecular biology from the University of Zurich. Following postdoctoral studies at the MRC Institute Mill Hill, London, he became a group leader at the University of Zurich. In 1987, he followed Max Birnstiel to the newly founded Research Institute of Molecular Pathology (IMP) in Vienna.

Busslinger is a Senior Scientist and Director of Academic Affairs at the IMP, Professor at the University of Vienna and a full member of the Austrian Academy of Sciences and of the European Molecular Biology Organisation EMBO. He has published over 130 papers in peer-reviewed journals and serves on the editorial boards of several scientific journals. Busslinger was awarded the Wittgenstein prize of the Austrian government in 2001 and the Virchow Medal by the University of Würzburg in 2010.

The recent allocation raises the number of ERC Grants awarded to IMP faculty to six: Barry Dickson succeeded in securing an advanced grant in the first round of evaluations in 2008. Stefan Westermann, Alexander Stark, Andrew Straw and Manuel Zimmer received ERC Starting Grants.

The Research Institute for Molecular Pathology carries out basic biomedical research in Vienna, Austria. Its main sponsor is Boehringer Ingelheim. Some 200 researchers from over 30 countries study life at molecular and cellular levels, information processing and storage in neural circuits, mechanisms of development and disease and interdisciplinary topics. The aim is a thorough understanding of complex biological processes that could lead to the development of new therapeutic concepts.

Contact:
IMP – Research Institute of Molecular Pathology
Dr. Heidemarie Hurtl, Communications
Tel. +43 1 797 30 – 3625
Mobile:+43 (0)664 8247910
hurtl@imp.ac.at
Scientific Contact
Prof. Meinrad Busslinger
busslinger@imp.ac.at

Dr. Heidemarie Hurtl | idw
Further information:
http://www.imp.ac.at/research/research-groups/busslinger-group/

More articles from Awards Funding:

nachricht Extensive Funding for Research on Chromatin, Adrenal Gland, and Cancer Therapy
28.06.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Otto Hahn Medal for Jaime Agudo-Canalejo
21.06.2017 | Max-Planck-Institut für Kolloid- und Grenzflächenforschung

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA looks to solar eclipse to help understand Earth's energy system

21.07.2017 | Earth Sciences

Stanford researchers develop a new type of soft, growing robot

21.07.2017 | Power and Electrical Engineering

Vortex photons from electrons in circular motion

21.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>